PlainPill

GW-501516 vs Tirzepatide for weight loss

Short answer: For weight loss, more users report improvement with Tirzepatide — 93% of 195 reports, versus 86% of 50 for GW-501516.

GW-501516 has 0 meta-analyses and 0 randomized trials on PubMed; Tirzepatide has 214 and 132.

Based on 307 reports about GW-501516 and 405 about Tirzepatide. Not medical advice.

GW-501516
Substance
Tirzepatide
Medication
User score4668
Verdict
Mostly positive
Mostly positive
Positive
of reports that state an outcome
64%76%
Reports307405
ResearchDResearch: NoneAResearch: Strong
Meta-analyses / RCTs0 / 0214 / 132
Mainly used for
Weight loss
% reporting improvement
86% (50)93% (195)
Appetite
% reporting improvement
50% (4)86% (71)
Focus
% reporting improvement
—67% (3)
Energy
% reporting improvement
95% (19)47% (30)
Sleep
% reporting improvement
0% (2)56% (9)
Mood
% reporting improvement
100% (2)68% (25)
Performance
% reporting improvement
93% (71)83% (12)
Recovery
% reporting improvement
100% (3)—
Pain & inflammation
% reporting improvement
—86% (7)
Digestion
% reporting improvement
—20% (5)
Libido
% reporting improvement
—33% (6)
Hormones
% reporting improvement
—50% (2)
Blood sugar
% reporting improvement
—80% (10)
Heart & lipids
% reporting improvement
89% (19)88% (8)
Skin & hair
% reporting improvement
—0% (2)
Longevity
% reporting improvement
50% (2)—
Common side effectscancer risk, acne, fatigue, brain fogfatigue, nausea, constipation, stomach issues
Typical dose reported20 mg7.5 mg
GW-501516
What a user said
“GW-501516 was a big one.”
Full GW-501516 profile →
Tirzepatide
Latest review conclusion

This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.

Pharmacol Res, 2021 ↗
What a user said
“mounjaro has been the best. I lost like 15 pounds in two months on this thing.”
Full Tirzepatide profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate